| Literature DB >> 29849872 |
Bruna Celeida Silva Santos1, Andressa Soares Pires1, Célia Hitomi Yamamoto2, Mara Rubia Costa Couri3, Alex Gutterres Taranto4, Maria Silvana Alves2, Ana Lúcia Dos Santos de Matos Araújo2, Orlando Vieira de Sousa2.
Abstract
This study investigated the in vitro and in silico biological properties of the methyl chavicol (MC) and its analogue 2-[(4-methoxyphenyl)methyl]oxirane (MPMO), emphasizing the antioxidant and antilipase effects. MPMO was synthesized from MC that reacted with meta-chloroperbenzoic acid and, after separation and purification, was identified by 1H and 13C NMR and GC-MS. The antioxidant activity was investigated by DPPH, cooxidation β-carotene/linoleic acid, and thiobarbituric acid assays. With the use of colorimetric determination, the antilipase effect on the pancreatic lipase was tested, while the molecular interaction profiles were evaluated by docking molecular study. MC (IC50 = 312.50 ± 2.28 μg/mL) and MPMO (IC50 = 8.29 ± 0.80 μg/mL) inhibited the DPPH free radical. The inhibition of lipid peroxidation (%) was 73.08 ± 4.79 and 36.16 ± 4.11 to MC and MPMO, respectively. The malonaldehyde content was significantly reduced in the presence of MC and MPMO. MC and MPMO inhibited the pancreatic lipase in 58.12 and 26.93%, respectively. MC and MPMO (-6.1 kcal·mol-1) produced a binding affinity value lower than did diundecylphosphatidylcholine (-5.6 kcal·mol-1). These findings show that MC and MPMO present antioxidant and antilipase activities, which may be promising molecular targets for the treatment of diseases associated with oxidative damage and lipid metabolism.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29849872 PMCID: PMC5925050 DOI: 10.1155/2018/2189348
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Scheme 1Oxidation reaction of methyl chavicol to obtain 2-[(4-methoxyphenyl)methyl]oxirane.
Figure 1Kinetic profile of the methyl chavicol and 2-[(4-methoxyphenyl)methyl]oxirane at different concentrations (mg/mL) against DPPH. The values correspond to the mean ± SEM (n = 3). (a) Methyl chavicol (50 to 750 mg/mL); (b) 2-[(4-methoxyphenyl)methyl]oxirane (5 to 75 mg/mL).
IC50 values of the methyl chavicol and 2-[(4-methoxyphenyl)methyl]oxirane by the DPPH method.
| Compound | IC50 (mg/mL) |
|---|---|
| BHT | 0.01 ± 0.01 |
| MC | 312.50 ± 2.28∗∗∗ |
| MPMO | 8.29 ± 0.80∗∗∗ |
The values correspond to the mean ± SEM (n = 3). BHT: 3,5-di-tert-butyl-4-hydroxy toluene; MC: methyl chavicol; MPMO: 2-[(4-methoxyphenyl)methyl]oxirane. The means differed from those of the positive control (BHT) after analysis of variance followed by Tukey's HSD (honest significant difference) test for ∗∗∗ P < 0.001.
Figure 2Decay of absorbance versus time by the cooxidation of the β-carotene/linoleic acid method. The values correspond to the mean ± SEM (n = 3). BHT: 3,5-di-tert-butyl-4-hydroxy toluene; MC: methyl chavicol; MPMO: 2-[(4-methoxyphenyl)methyl]oxirane. The means differed from those of the negative control after analysis of variance followed by Tukey's HSD (honest significant difference) test for ∗∗∗ P < 0.001.
Inhibition of lipid peroxidation by the cooxidation of the β-carotene/linoleic acid method.
| Compound | Inhibition of lipid peroxidation (%) |
|---|---|
| BHT | 59.66 ± 0.52 |
| MC | 73.08 ± 4.79∗∗∗ |
| MPMO | 36.16 ± 4.11∗∗∗ |
The values correspond to the mean ± SEM (n = 3). BHT: 3,5-di-tert-butyl-4-hydroxy toluene; MC: methyl chavicol; MPMO: 2-[(4-methoxyphenyl)methyl]oxirane. The means differed from those of the positive control (BHT) after analysis of variance followed by Tukey's HSD (honest significant difference) test for ∗∗∗ P < 0.001.
Concentration of malonaldehyde (MDA) obtained by the thiobarbituric acid method.
| Sample | Concentration (mg) | MDA content ( | ||||
|---|---|---|---|---|---|---|
| Day 0 | Day 1 | Day 2 | Day 3 | Day 4 | ||
| Control | Saline | 0.42 ± 0.02 | 0.59 ± 0.04 | 0.67 ± 0.06 | 0.64 ± 0.03 | 0.91 ± 0.08 |
|
| ||||||
| BHT | 7.5 | 0.08 ± 0.02∗∗∗ | 0.16 ± 0.02∗∗∗ | 0.12 ± 0.03∗∗∗ | 0.16 ± 0.00∗∗∗ | 0.22 ± 0.05∗∗∗ |
| 15 | 0.10 ± 0.02∗∗∗ | 0.11 ± 0.03∗∗∗ | 0.08 ± 0.01∗∗∗ | 0.17 ± 0.06∗∗∗ | 0.16 ± 0.01∗∗∗ | |
| 30 | 0.20 ± 0.01∗∗∗ | 0.20 ± 0.03∗∗∗ | 0.23 ± 0.06∗∗∗ | 0.12 ± 0.08∗∗∗ | 0.22 ± 0.08∗∗∗ | |
|
| ||||||
| MC | 7.5 | 0.41 ± 0.01 | 0.18 ± 0.02∗∗∗ | 0.22 ± 0.06∗∗∗ | 0.22 ± 0.06∗∗∗ | 0.16 ± 0.02∗∗∗ |
| 15 | 0.39 ± 0.06 | 0.29 ± 0.04∗∗∗ | 0.53 ± 0.06∗∗∗ | 0.32 ± 0.07∗∗∗ | 0.21 ± 0.08∗∗∗ | |
| 30 | 0.35 ± 0.02∗∗∗ | 0.20 ± 0.01∗∗∗ | 0.40 ± 0.06∗∗∗ | 0.38 ± 0.03∗∗∗ | 0.22 ± 0.02∗∗∗ | |
|
| ||||||
| MPMO | 7.5 | 0.24 ± 0.02∗∗∗ | 0.39 ± 0.07∗∗∗ | 0.46 ± 0.01∗∗∗ | 0.35 ± 0.03∗∗∗ | 0.54 ± 0.04∗∗∗ |
| 15 | 0.20 ± 0.01∗∗∗ | 0.25 ± 0.00∗∗∗ | 0.37 ± 0.05∗∗∗ | 0.39 ± 0.01∗∗∗ | 0.38 ± 0.01∗∗∗ | |
| 30 | 0.18 ± 0.06∗∗∗ | 0.26 ± 0.02∗∗∗ | 0.32 ± 0.00∗∗∗ | 0.37 ± 0.01∗∗∗ | 0.34 ± 0.05∗∗∗ | |
The values correspond to the mean ± SEM (n = 3). BHT: 3,5-di-tert-butyl-4-hydroxy toluene; MC: methyl chavicol; MPMO: 2-[(4-methoxyphenyl)methyl]oxirane. The means differed from those of the negative control (saline) after analysis of variance followed by Tukey's HSD (honest significant difference) test for ∗∗∗ P < 0.001.
Figure 3Inhibitory effect of the methyl chavicol and 2-[(4-methoxyphenyl)methyl]oxirane on the pancreatic lipase. The values correspond to the mean ± SEM (n = 3). MC: methyl chavicol (10 mg/mL); MPMO: 2-[(4-methoxyphenyl)methyl]oxirane (10 mg/mL). The means differed from those of the positive control (orlistat) after analysis of variance followed by Tukey's HSD (honest significant difference) test for ∗∗∗ P < 0.001.
Binding affinity between ligands and pancreatic lipase.
| Compound | Binding affinity (kcal·mol−1) |
|---|---|
| PLC | −5.6 |
| Orlistat | −6.5 |
| MC | −6.1 |
| MPMO | −6.1 |
PLC: diundecylphosphatidylcholine; MC: methyl chavicol; MPMO: 2-[(4-methoxyphenyl)methyl]oxirane.
Scheme 2Proposal of the antioxidant mechanism of the methyl chavicol and 2-[(4-methoxyphenyl)methyl]oxirane based on the reaction with DPPH. (a) Stages of reactions between methyl chavicol and DPPH. (b) Stages of reactions between 2-[(4-methoxyphenyl)methyl]oxirane and DPPH.